3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Neoplasm Metastasis
1
Carcinoma, Squamous Cell
1
Interventions
pembrolizumab
61
Cisplatin
37
Carboplatin
23
Radiotherapy
21
Cetuximab
19
Magnetic Resonance Spectroscopy
18
Paclitaxel
17
Specimen Handling
13
Docetaxel
12
Fluorouracil
11
Nivolumab
10
tislelizumab
9
Surgical Procedures, Operative
8
Radiotherapy, Intensity-Modulated
7
Radiation
7
cemiplimab
6
Standard of Care
6
Platinum
6
Chemoradiotherapy
6
Biopsy
6
1,2-diaminocyclohexaneplatinum II citrate
6
toripalimab
5
Drug Therapy
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Taxes
4
Ipilimumab
4
Immunotherapy
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Squamous Cell Carcinoma of Head and Neck
×
ficlatuzumab
×
Clear all
NCT06064877
2026-04-09
FIERCE-HN
AVEO Pharmaceuticals, Inc.
Phase 3
Recruiting
410 enrolled